Detail akcie Affluent Med online

Business Summary: Carvolix is a France-based company. The Company is engaged in developing Artificial Intelligence (AI)-driven autonomous mini-robots and biomimetic implants for interventional cardiology and stroke treatment. It operates through the consolidation, Caranx Medical, and Artedrone, and focuses on technologies used in cardiac valve replacement, structural heart interventions, and neurovascular procedures. It develops systems combining micro-robotics, artificial intelligence, imaging guidance, and implantable heart devices. Its product portfolio includes the TAVIPILOT software for transcatheter aortic valve implantation (TAVI), structural heart devices such as Kalios and Epygon, the Artus artificial urinary sphincter, and a robotic platform intended for stroke treatment.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Carvolix SA revenues decreased from EUR4.1M to EUR0K. Net loss increased 69% to EUR25M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Provisions net of reversals increase from EUR11K (income) to EUR15K (expense), Taxes and duties increase of 15% to EUR75K (expense).